NEW YORK (GenomeWeb) – Molecular diagnostics firm Rosetta Genomics announced today that it will effect a 1-for-12 reverse stock split in order to help regain compliance with the Nasdaq Capital Market's listing requirements.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect.
This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.
This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.